Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia
Recruiting
Phase 2
Interventional Study
COPD (Chronic Obstructive Pulmonary Disease)
Hypoxemia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 40 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 10 (estimated)
- Sponsor
- Bastiaan Driehuys · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to evaluate whether inhaled Treprostinil (Tyvaso) can improve oxygen delivery and blood flow in the lungs in adults (age ≥40) with chronic obstructive pulmonary disease (COPD) and hypoxemia who have less severe reduction in lung blood volume (diffusing capacity of the lungs for carbon monoxide \[DLCO\] ≥45%).
The main questions it aims to answer are:
1. Does in…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria
* Outpatients of either gender, age ≥ 40.
* Clinical evidence of chronic bronchitis (a productive cough lasting more than 3 months within a 2-year period).
* Current or former cigarette smokers with a smoking history of 20 or more pack-years.
* Clinical diagnosis of chronic obstr…
Contacts